Ubiquitin-specific peptidases in lymphoma: a path to novel therapeutics
BackgroundUbiquitin-specific peptidases (USPs), also known as deubiquitinating enzymes (DUBs), play a crucial role in maintaining cellular homeostasis by selectively removing ubiquitin molecules from targeted proteins. This process affects protein stability, subcellular localization, and activity, t...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-11-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1356634/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850225941278621696 |
|---|---|
| author | Maryam Samareh Salavatipour Shirin Tavakoli Aram Halimi Aram Halimi Shima Tavoosi Amir-Hossein Baghsheikhi Abdolkarim Talebi-Taheri Mehdi Niloufari Zahra Salehi Javad Verdi Soheila Rahgozar Alireza Mosavi-Jarrahi Mohammad Ahmadvand |
| author_facet | Maryam Samareh Salavatipour Shirin Tavakoli Aram Halimi Aram Halimi Shima Tavoosi Amir-Hossein Baghsheikhi Abdolkarim Talebi-Taheri Mehdi Niloufari Zahra Salehi Javad Verdi Soheila Rahgozar Alireza Mosavi-Jarrahi Mohammad Ahmadvand |
| author_sort | Maryam Samareh Salavatipour |
| collection | DOAJ |
| description | BackgroundUbiquitin-specific peptidases (USPs), also known as deubiquitinating enzymes (DUBs), play a crucial role in maintaining cellular homeostasis by selectively removing ubiquitin molecules from targeted proteins. This process affects protein stability, subcellular localization, and activity, thereby influencing processes such as DNA repair, cell cycle regulation, and apoptosis. Abnormal USP activities have been linked to various diseases, including cancer. Emerging evidence in lymphoma studies highlights the significance of USPs in controlling signaling pathways related to cancer initiation and progression and presents them as potential therapeutic targets.AimThis study aimed to elucidate the multifaceted roles of USPs in lymphoma.MethodsThis systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Articles published in English up to May 2023 were retrieved from PubMed, Web of Science, and Scopus. The inclusion criteria focused on studies investigating the role of USPs in lymphoma cancer, involving human subjects or relevant lymphoma cell lines, exploring molecular mechanisms and signaling pathways, and assessing diagnostic or prognostic value.ResultsAfter the selection process, 23 studies were selected for analysis. USPs were found to affect various aspects of lymphoma development and progression. Specific USPs were identified with roles in cell-cycle regulation, apoptosis modulation, drug resistance, DNA repair, and influence of key oncogenic pathways, such as B cell receptor (BCR) signaling.ConclusionThis systematic review underscores the emerging role of USPs in lymphoma and their potential as therapeutic targets. Inhibitors of USPs, such as USP14 inhibitors, show promise in overcoming drug resistance. The dynamic interplay between USPs and lymphoma biology presents an exciting opportunity for future research and the development of more effective treatments for patients with lymphoma. Understanding the intricate functions of USPs in lymphoma offers new insights into potential therapeutic strategies, emphasizing the significance of these enzymes in the context of cancer biology. |
| format | Article |
| id | doaj-art-3d00cdd4e62642448f40e495e5e0ee4f |
| institution | OA Journals |
| issn | 1663-9812 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-3d00cdd4e62642448f40e495e5e0ee4f2025-08-20T02:05:13ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122024-11-011510.3389/fphar.2024.13566341356634Ubiquitin-specific peptidases in lymphoma: a path to novel therapeuticsMaryam Samareh Salavatipour0Shirin Tavakoli1Aram Halimi2Aram Halimi3Shima Tavoosi4Amir-Hossein Baghsheikhi5Abdolkarim Talebi-Taheri6Mehdi Niloufari7Zahra Salehi8Javad Verdi9Soheila Rahgozar10Alireza Mosavi-Jarrahi11Mohammad Ahmadvand12Department of Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, IranDepartment of Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, IranDepartment of Epidemiology, School of Public Health and Safety, Shahid Beheshti University of Medical Sciences, Tehran, IranResearch Center for Social Determinants of Health, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, IranDepartment of Cell and Molecular Biology and Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, IranDepartment of Biology, Science and Research Branch, Islamic Azad University, Tehran, IranStudent Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IranShahid Beheshti University of Medical Sciences, Tehran, IranHematology, Oncology and Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, IranDepartment of Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, IranDepartment of Cell and Molecular Biology and Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, IranCancer Research Centre, Shahid Beheshti University of Medical Sciences, TehranIran0Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology, and Cell Therapy, Tehran University of Medical Sciences, Tehran, IranBackgroundUbiquitin-specific peptidases (USPs), also known as deubiquitinating enzymes (DUBs), play a crucial role in maintaining cellular homeostasis by selectively removing ubiquitin molecules from targeted proteins. This process affects protein stability, subcellular localization, and activity, thereby influencing processes such as DNA repair, cell cycle regulation, and apoptosis. Abnormal USP activities have been linked to various diseases, including cancer. Emerging evidence in lymphoma studies highlights the significance of USPs in controlling signaling pathways related to cancer initiation and progression and presents them as potential therapeutic targets.AimThis study aimed to elucidate the multifaceted roles of USPs in lymphoma.MethodsThis systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Articles published in English up to May 2023 were retrieved from PubMed, Web of Science, and Scopus. The inclusion criteria focused on studies investigating the role of USPs in lymphoma cancer, involving human subjects or relevant lymphoma cell lines, exploring molecular mechanisms and signaling pathways, and assessing diagnostic or prognostic value.ResultsAfter the selection process, 23 studies were selected for analysis. USPs were found to affect various aspects of lymphoma development and progression. Specific USPs were identified with roles in cell-cycle regulation, apoptosis modulation, drug resistance, DNA repair, and influence of key oncogenic pathways, such as B cell receptor (BCR) signaling.ConclusionThis systematic review underscores the emerging role of USPs in lymphoma and their potential as therapeutic targets. Inhibitors of USPs, such as USP14 inhibitors, show promise in overcoming drug resistance. The dynamic interplay between USPs and lymphoma biology presents an exciting opportunity for future research and the development of more effective treatments for patients with lymphoma. Understanding the intricate functions of USPs in lymphoma offers new insights into potential therapeutic strategies, emphasizing the significance of these enzymes in the context of cancer biology.https://www.frontiersin.org/articles/10.3389/fphar.2024.1356634/fullubiquitin-specific peptidasesUSPscancerlymphomanon-HodgkinHodgkin |
| spellingShingle | Maryam Samareh Salavatipour Shirin Tavakoli Aram Halimi Aram Halimi Shima Tavoosi Amir-Hossein Baghsheikhi Abdolkarim Talebi-Taheri Mehdi Niloufari Zahra Salehi Javad Verdi Soheila Rahgozar Alireza Mosavi-Jarrahi Mohammad Ahmadvand Ubiquitin-specific peptidases in lymphoma: a path to novel therapeutics Frontiers in Pharmacology ubiquitin-specific peptidases USPs cancer lymphoma non-Hodgkin Hodgkin |
| title | Ubiquitin-specific peptidases in lymphoma: a path to novel therapeutics |
| title_full | Ubiquitin-specific peptidases in lymphoma: a path to novel therapeutics |
| title_fullStr | Ubiquitin-specific peptidases in lymphoma: a path to novel therapeutics |
| title_full_unstemmed | Ubiquitin-specific peptidases in lymphoma: a path to novel therapeutics |
| title_short | Ubiquitin-specific peptidases in lymphoma: a path to novel therapeutics |
| title_sort | ubiquitin specific peptidases in lymphoma a path to novel therapeutics |
| topic | ubiquitin-specific peptidases USPs cancer lymphoma non-Hodgkin Hodgkin |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2024.1356634/full |
| work_keys_str_mv | AT maryamsamarehsalavatipour ubiquitinspecificpeptidasesinlymphomaapathtonoveltherapeutics AT shirintavakoli ubiquitinspecificpeptidasesinlymphomaapathtonoveltherapeutics AT aramhalimi ubiquitinspecificpeptidasesinlymphomaapathtonoveltherapeutics AT aramhalimi ubiquitinspecificpeptidasesinlymphomaapathtonoveltherapeutics AT shimatavoosi ubiquitinspecificpeptidasesinlymphomaapathtonoveltherapeutics AT amirhosseinbaghsheikhi ubiquitinspecificpeptidasesinlymphomaapathtonoveltherapeutics AT abdolkarimtalebitaheri ubiquitinspecificpeptidasesinlymphomaapathtonoveltherapeutics AT mehdiniloufari ubiquitinspecificpeptidasesinlymphomaapathtonoveltherapeutics AT zahrasalehi ubiquitinspecificpeptidasesinlymphomaapathtonoveltherapeutics AT javadverdi ubiquitinspecificpeptidasesinlymphomaapathtonoveltherapeutics AT soheilarahgozar ubiquitinspecificpeptidasesinlymphomaapathtonoveltherapeutics AT alirezamosavijarrahi ubiquitinspecificpeptidasesinlymphomaapathtonoveltherapeutics AT mohammadahmadvand ubiquitinspecificpeptidasesinlymphomaapathtonoveltherapeutics |